PharmaShots Weekly Snapshots (March 20 - 24, 2023)
Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE
Date: Mar 24, 2023 | Tags: Onconova Therapeutics, Pangea Biomed, Rigosertib, Nivolumab, Biomarkers, Squamous Cell Carcinoma, ENLIGHT platform, Biotech
Date: Mar 24, 2023 | Tags: Boehringer Ingelheim, Spevigo, spesolimab, Generalized Pustular Psoriasis, Regulatory, Health Canada, Marketing Authorization
Date: Mar 24, 2023 | Tags: AbbVie, Skyrizi, Risankizumab, Ulcerative Colitis, Clinical Trial, P-III, INSPIRE, Induction Study
AstraZeneca’s Calquence (acalabrutinib) Receives the NMPA’s Approval for Mantle Cell Lymphoma
Date: Mar 24, 2023 | Tags: AstraZeneca, Calquence, acalabrutinib, Mantle Cell Lymphoma, Regulatory, NMPA, Approval
Date: Mar 24, 2023 | Tags: Macomics, Ono, Macrophage-targeting, Antibody, Cancer, ENIGMACT macrophage drug discovery platform, Pharma
Date: Mar 23, 2023 | Tags: Ono Pharmaceutical, Opdivo, nivolumab, Yervoy, ipilimumab, Esophageal Squamous Cell Carcinoma, Regulatory, MFDS
Date: Mar 23, 2023 | Tags: Ancora Heart, AccuCinch System, Heart Failure, Clinical Trial, MedTech
Date: Mar 23, 2023 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, Chronic Obstructive Pulmonary Disease, Clinical Trial, P-III, BOREAS Trial
Date: Mar 23, 2023 | Tags: Incyte, Zynyz, retifanlimab-Dlwr, Merkel Cell Carcinoma, Regulatory, US, FDA, Approval
Biohaven Acquires Rights for BHV-8000 to Treat Immune-Mediated Brain Disorders
Date: Mar 23, 2023 | Tags: Biohaven, BHV-8000, TLL-041, Immune-Mediated Brain Disorders, Pharma
Date: Mar 23, 2023 | Tags: Dewpoint Therapeutics, Novo Nordisk, AI technology platform, Insulin Resistance, Diabetes Progression, Pharma
Date: Mar 22, 2023 | Tags: TaiGen, Joincare, TG-1000, China, Pharma
Medtronic Collaborated with NVIDIA to Advance the Development of AI in the Healthcare Industry
Date: Mar 22, 2023 | Tags: Medtronic, NVIDIA, AI, NVIDIA Holoscan & NVIDIA IGX, GI Genius, colorectal cancer, DigiHealth
Date: Mar 22, 2023 | Tags: Jacobio, Merck, JAB-BX102, Keytruda, pembrolizumab, pablizumab, Solid Tumors, Pharma
Date: Mar 22, 2023 | Tags: Lumicell, Lumisight Optical Imaging Agent, Intraoperative Breast Cancer, Regulatory, US, FDA, NDA
Date: Mar 22, 2023 | Tags: Altimmune, Pemvidutide, Obesity, Type 2 Diabetes, Clinical Trial, P-II, MOMENTUM, P-Ib Trial
Date: Mar 22, 2023 | Tags: Kite, Yescarta, Large B-cell Lymphoma, Clinical Trial, P-III, ZUMA-7 Study
Date: Mar 21, 2023 | Tags: OrsoBio, TLC-3595, Type 2 Diabetes, Clinical Trial, P-II Trial
Selecta and Sobi Report P-III Trial (DISSOLVE I & II) Results of SEL-212 for Chronic Refractory Gout
Date: Mar 21, 2023 | Tags: Selecta, Sobi, SEL-212, Chronic Refractory Gout, Clinical Trial, P-III, DISSOLVE I & II Trial
Date: Mar 21, 2023 | Tags: Regeneron, Dupixent, dupilumab, Atopic Dermatitis, Regulatory, EC, Approval
CHARM Therapeutics Collaborated with BMS to Advance Small Molecule Drug Discovery Programs
Date: Mar 21, 2023 | Tags: Bristol Myers Squibb, CHARM Therapeutics, Small Molecule, Drug Discovery, DragonFold deep learning platform, Pharma
Gilead Exercises its Option to License Nurix’s NX-0479 for Cancer
Date: Mar 21, 2023 | Tags: Gilead, Nurix, NX-0479, GS-6791 Cancer, Biotech
Date: Mar 21, 2023 | Tags: BioNTech, OncoC4, ONC-392, Solid Tumor, Non-small cell lung cancer, Pharma
Date: Mar 20, 2023 | Tags: Coya Therapeutics, Dr. Reddy’s Laboratories, Abatacept, COYA 302, neurodegenerative diseases, Pharma
Date: Mar 20, 2023 | Tags: UCB, Bimekizumab, Hidradenitis Suppurativa, Clinical Trial, P-III, BE HEARD I, BE HEARD II Trial
Takeda Reports P-IIb Trial Results TAK-279 for the Treatment of Plaque Psoriasis
Date: Mar 20, 2023 | Tags: Takeda, TAK-279, Plaque Psoriasis, Clinical Trial, P-IIb Trial
Date: Mar 20, 2023 | Tags: DermaSensor, Device, Skin Cancer, Clinical Trial, DERM-ASSESS III, DERM-SUCCESS Clinical, Clinical Trial, MedTech
Galderma Presents P-III Trial (OLYMPIA 2) of Nemolizumab for Prurigo Nodularis at AAD 2023
Date: Mar 20, 2023 | Tags: Galderma, Nemolizumab, Prurigo Nodularis, Clinical Trial, P-III, OLYMPIA 2 Trial, AAD, 2023
Date: Mar 20, 2023 | Tags: Regeneron, Dupixent, dupilumab, Atopic Hand, Foot Dermatitis, Clinical Trial, P-III Trial, AAD, 2023
Related Post: PharmaShots Weekly Snapshots (March 13 - 17, 2023)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.